Follicular regulatory T (Tfr) cells enter the B-cell follicle and germinal center, where they control the magnitude, specificity, and duration of the antibody response. However, the temporal and spatial determinants of Tfr differentiation are incompletely understood. Recent advances in fate-mapping, single-cell transcr...
Jeong-Mi Lee, P. Sage· Trends in immunology· 0 citations
The findings suggest that CAR19 Tregs represent a promising and safe cGVHD/BOS therapeutic strategy, offering immunosuppressive benefits and improved disease outcomes that may be more limited with CD8+ CAR19 T cell treatment.
Sujeong Jin, Michael C. Zaiken, Cameron McDonald-Hyman et al.· JCI Insight· 0 citations
Genetic Id2 loss uncouples Tfh differentiation from effector activity, positioning Id2 inhibition as a novel therapeutic strategy to selectively disrupt pathogenic Tfh-GCB crosstalk in cGVHD.
Yujie Zhao, Eun Ko, Cameron McDonald-Hyman et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.